Clinicopathological significance of fascin-1 expression in patients with non-small cell lung cancer

Figures & data

Figure 1 Fascin-1 expression in NSCLC tissues (SP ×100).

Notes: (A) Nucleus staining of squamous cell carcinoma; (B) cytoplasm staining of squamous cell carcinoma; (C) nucleus staining of adenocarcinoma; (D) cytoplasm staining of adenocarcinoma.
Abbreviation: NSCLC, non-small cell lung cancer.

Figure 2 Fascin-1 mRNA was detected by RT-PCR.

Abbreviations: NSCLC, non-small cell lung cancer; RT-PCR, real-time polymerase chain reaction.

Figure 3 Fascin-1 protein was detected by western blot analysis.

Abbreviation: NSCLC, non-small cell lung cancer.

Table 1 Correlation of clinicopathologic variables with fascin-1 protein in NSCLC

Variables	N	Fascin-1 expression
		High	Low	χ^2	P-value
Age (years)				0.634	0.426
<60	74	40	34
≥60	54	33	21
Sex				0.005	0.941
Male	74	42	32
Female	54	31	23
Smoking history				2.279	0.131
Yes	60	30	30
No	68	43	25
Histological type				0.347	0.556
SCC	73	40	33
AD	55	33	22
Differentiation				2.114	0.347
Well	28	19	9
Moderate	62	35	27
Poor	38	19	19
Tumor size (cm)				0.006	0.938
≤3	60	34	26
>3	68	39	29
Lymph node metastasis				5.274	0.022
N0	55	25	30
N1 + N2	73	48	25
TNM stage				4.135	0.042
Stage I	39	17	22
Stage II + III	89	56	33

Abbreviations: SCC, squamous cell carcinoma; AD, adenocarcinoma; NSCLC, non-small cell lung cancer.

Figure 4 Kaplan–Meier curves of DFS and OS.

Notes: (A) DFS of all patients with NSCLC, (B) OS of all patients with NSCLC, (C) OS according to lymph node metastasis in patients with NSCLC, and (D) OS according to stage in patients with NSCLC.
Abbreviations: DFS, disease-free survival; OS, overall survival.

Table 2 DFS and OS of NSCLC patients according to fascin-1 expression

	N	Survival time (months)		P-value
		Mean ± SE	95% CI
DFS				0.001
Low expression	55	41.15±2.83	35.59–46.70
High expression	73	29.52±2.21	25.18–33.86
OS				0.004
Low expression	55	52.33±2.95	46.55–58.10
High expression	73	41.30±2.55	36.30–46.30

Abbreviations: NSCLC, non-small cell lung cancer; DFS, disease-free survival; OS, overall survival; CI, confidence interval, SE, standard error.

Table 3 Univariate and multivariate analysis for overall survival

Variables	Univariate analyses HR for death (95% CI)	P-value	Multivariate analysis HR for death (95% CI)	P-value
Age	1.05 (0.67–1.66)	0.830	0.93 (0.58–1.48)	0.752
Sex	1.08 (0.69–1.71)	0.728	1.02 (0.64–1.63)	0.921
Smoking	1.55 (0.98–2.47)	0.062	1.56 (0.97–2.5)	0.065
Histology	0.96 (0.61–1.51)	0.849	0.74 (0.45–1.19)	0.214
Differentiation	0.97 (0.70–1.33)	0.844	0.94 (0.68–1.32)	0.736
Tumor size	1.05 (0.67–1.65)	0.834	0.93 (0.58–1.49)	0.769
Lymph node metastasis	2.47 (1.50–4.06)	<0.001	2.09 (1.24–3.51)	0.006
TNM stage	2.87 (1.58–5.24)	0.001	2.51 (1.34–4.7)	0.004
Fascin-1 expression	1.99 (1.22–3.23)	0.006	1.7 (1.02–2.83)	0.043

Abbreviations: CI, confidence interval; HR, hazard ratio.